OMERS ADMINISTRATION Corp Takes $922,000 Position in Zimmer Biomet Holdings, Inc. $ZBH

OMERS ADMINISTRATION Corp purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, HoldingsChannel reports. The fund purchased 10,708 shares of the medical equipment provider’s stock, valued at approximately $922,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZBH. Osmosis Investment Management UK Ltd purchased a new stake in shares of Zimmer Biomet in the second quarter valued at $352,000. Sanctuary Advisors LLC purchased a new position in shares of Zimmer Biomet during the second quarter valued at $1,781,000. Magellan Asset Management Ltd acquired a new position in Zimmer Biomet during the second quarter valued at $49,107,000. Bank of Nova Scotia acquired a new position in Zimmer Biomet during the second quarter valued at $1,483,000. Finally, Commerce Bank purchased a new stake in Zimmer Biomet in the 2nd quarter worth about $1,114,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on ZBH. Sanford C. Bernstein lifted their target price on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Truist Financial boosted their price objective on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a research report on Thursday, August 6th. Citigroup dropped their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Finally, UBS Group reissued a “buy” rating and set a $120.00 target price on shares of Zimmer Biomet in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Stock Down 2.0%

ZBH opened at $99.40 on Friday. The company has a market capitalization of $18.96 billion, a PE ratio of 24.19, a price-to-earnings-growth ratio of 2.76 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $106.88. The business has a 50-day moving average of $93.63 and a 200-day moving average of $91.38.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the previous year, the business posted $2.07 EPS. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.